Articles

Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

Olaparib Significantly Improves Survival in Men with Metastatic Prostate Cancer and BRCA Mutations

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer

By Patricia Stewart

ESMO, ESMO 2020

TON - December 2020, Vol 13, No 6

Opportunities for Innovation in Value-Based Payments in Oncology

Value-Based Care

TON - December 2020, Vol 13, No 6

Can We Lower the Cost of Cancer Care?

Value-Based Care

TON - December 2020, Vol 13, No 6

Personalized Vaccine plus Atezolizumab Shows Promising Clinical Activity in Advanced Cancer

By Patricia Stewart

TON - December 2020, Vol 13, No 6

Understanding Social Determinants of Health and Their Impact on Cancer Care

By Charlie Dawson

Quality Care Symposium

TON - December 2020, Vol 13, No 6

FDA NEWS December 2020

TON - December 2020, Vol 13, No 6

Innovations in Quality Care During the COVID-19 Pandemic: Lessons Learned

By Charlie Dawson

Quality Care Symposium

TON - December 2020, Vol 13, No 6

Financial Hardship Can Affect Long-Term Outcomes in Patients with Cancer

By Charlie Dawson

Quality Care Symposium

TON - December 2020, Vol 13, No 6

Protecting patients with cancer from financial hardship can save more than money. According to data presented at the 2020 ASCO Quality Care Symposium, mitigating the financial burden of cancer treatment on patients may save lives as well. Read More ›

Page 107 of 376

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.